Mariner, LLC Recursion Pharmaceuticals, Inc. Transaction History

Mariner, LLC

$55.8 Billion
Q3 2024

A detailed history of Mariner, LLC transactions in Recursion Pharmaceuticals, Inc. stock. As of the latest transaction made, Mariner, LLC holds 83,564 shares of RXRX stock, worth $621,716. This represents 0.0% of its overall portfolio holdings.

Number of Shares

83,564

Previous 81,095 3.04%

Holding current value

$621,716

Previous $608,000 9.54%

% of portfolio

0.0%

Previous 0.0%

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 13, 2024	BUY	$5.92 - $8.6 $14,616 - $21,233	2,469 Added 3.04%	83,564 $550,000
Q2 2024 Aug 13, 2024	BUY	$7.35 - $10.05 $8,761 - $11,979	1,192 Added 1.49%	81,095 $608,000
Q1 2024 May 15, 2024	BUY	$9.13 - $15.52 $474 - $807	52 Added 0.07%	79,903 $796,000
Q4 2023 Feb 14, 2024	SELL	$5.09 - $10.79 $3,074 - $6,517	-604 Reduced 0.75%	79,851 $787,000
Q3 2023 Nov 13, 2023	SELL	$6.59 - $15.86 $333,289 - $802,119	-50,575 Reduced 38.6%	80,455 $615,000
Q2 2023 Aug 11, 2023	SELL	$4.56 - $9.94 $278,734 - $607,592	-61,126 Reduced 31.81%	131,030 $978,000
Q1 2023 May 12, 2023	SELL	$6.42 - $9.64 $42,172 - $63,325	-6,569 Reduced 3.31%	192,156 $1.28 Million
Q4 2022 Feb 14, 2023	SELL	$7.16 - $12.7 $5,463 - $9,690	-763 Reduced 0.38%	198,725 $1.53 Million
Q3 2022 Nov 10, 2022	BUY	$7.83 - $13.6 $195,366 - $339,333	24,951 Added 14.3%	199,488 $2.12 Million
Q2 2022 Aug 15, 2022	BUY	$5.04 - $9.26 $737,946 - $1.36 Million	146,418 Added 520.71%	174,537 $1.42 Million
Q1 2022 May 13, 2022	BUY	$6.16 - $18.03 $173,213 - $506,985	28,119 New	28,119 $201,000

Others Institutions Holding RXRX

# of Institutions

287

Shares Held

242M

Call Options Held

1.35M

Put Options Held

2.32M

View Full List

About RECURSION PHARMACEUTICALS, INC.

Ticker RXRX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 180,480,000
Market Cap $1.34B
Description
Recursion Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase IIa clinical trial to treat cerebral cav...

More about RXRX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Mariner, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Mariner, LLC with notifications on news.

Account